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Background: The disruption of endothelial homeostasis is a major determinant in the pathogenesis of systemic
sclerosis (SSc) and is reflected by soluble and cellular markers of activation, injury and repair. We aimed to provide a
combined assessment of endothelial markers to delineate specific profiles associated with SSc disease and its severity.
Methods: We conducted an observational, single-centre study comprising 45 patients with SSc and 41 healthy control
subjects. Flow cytometry was used to quantify circulating endothelial microparticles (EMPs) and CD34+ progenitor cell
subsets. Colony-forming unit-endothelial cells (CFU-ECs) were counted by culture assay. Circulating endothelial cells were
enumerated using anti-CD146-based immunomagnetic separation. Blood levels of endothelin-1, vascular endothelial
growth factor (VEGF) and soluble fractalkine (s-Fractalkine) were evaluated by enzyme-linked immunosorbent assay.
Disease-associated markers were identified using univariate, correlation and multivariate analyses.
Results: Enhanced numbers of EMPs, CFU-ECs and non-haematopoietic CD34+CD45− endothelial progenitor cells (EPCs)
were observed in patients with SSc. Patients with SSc also displayed higher serum levels of VEGF, endothelin-1 and
s-Fractalkine. s-Fractalkine levels positively correlated with CD34+CD45− EPC numbers. EMPs, s-Fractalkine and
endothelin-1 were independent factors associated with SSc. Patients with high CD34+CD45− EPC numbers had lower
forced vital capacity values. Elevated s-Fractalkine levels were associated with disease severity, a higher frequency of
pulmonary fibrosis and altered carbon monoxide diffusion.
Conclusions: This study identifies the mobilisation of CD34+CD45− EPCs and high levels of s-Fractalkine as specific
features of SSc-associated vascular activation and disease severity. This signature may provide novel insights linking
endothelial inflammation and defective repair processes in the pathogenesis of SSc.
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Systemic sclerosis (SSc) is a systemic autoimmune dis-
ease characterised by vascular damage and fibrosis [1].
The blood vessel is the primary target for both initiating
and propagating the local immune activation and fibro-
sis. This vascular hypothesis has been underscored by
the impairment of the flow-mediated dilation (FMD) of
the brachial artery, a validated, non-invasive physio-
logical measure of endothelial function [2].
The disruption of endothelial integrity involves an
altered balance between lesion and repair processes that
can be assessed by non-invasive endothelium-derived bio-
markers which our group has contributed to identify and
standardise [3, 4]. These markers include circulating endo-
thelial cells (CECs) that enter the bloodstream following
detachment of stressed endothelial cells from the vessel
wall and endothelial microparticles (EMPs) that are shed
during the membrane remodelling of activated or apop-
totic endothelial cells. These markers have been shown to
have diagnostic and prognostic value in cardiovascular
diseases [4–6], but their significance in inflammatory and
autoimmune diseases is less well established [7–9].
In response to vascular injury, endothelial repair
mechanisms have been shown to involve the recruitment
of progenitor cells (PCs) [10]. In their pioneering work,
Asahara et al. [10] identified a bone marrow-derived cir-
culating population of PCs expressing CD34 and kinase
insert domain receptor (KDR, vascular endothelial
growth factor receptor 2 [VEGFR-2]) antigens that dis-
plays the capacity to differentiate into an endothelial
phenotype and contribute to physiological or patho-
logical neovascularisation. These cells were referred to
as endothelial progenitor cells (EPCs).
From that time, extensive research has led to the recogni-
tion that EPCs represent a highly heterogeneous cell com-
partment. Indeed, various circulating subpopulations with
different stages of maturation, lineage origin and functional
properties contribute to the “EPC pool” [11, 12]. Following
the first report of decreased levels of circulating EPCs in
SSc [13], several controversial studies have addressed their
quantitative and functional alterations [14–23]. These dis-
crepancies may arise from the clinical characteristics of the
enrolled patients with SSc and the disparate methodologies
used to analyse EPCs. Indeed, despite the effort to find a
consensus [22], these methods based on flow cytometric
analyses or on ex vivo culture protocols have sometimes
led to the assessment of distinct cell populations.
Importantly, most of the literature in the SSc field has
focused on cells that belong to the haematopoietic
lineage [23]. Indeed, recent clarifications in EPC identity
indicate that a combination of CD34, CD133 and KDR
markers enumerate mostly bone marrow-derived
haematopoietic cells or progenitors that correlate with
vascular endothelial status [11]. These cells are nowdesignated as circulating angiogenic cells (CACs) to
reflect their potential to sustain angiogenesis but lack de
novo vessel-forming activity [24]. Additionally, the
colony-forming unit-endothelial cell (CFU-EC) assay in-
troduced by Hill et al. allowed for the description of the
CFU-ECs as relevant biomarkers of cardiovascular risk
[25]. Increased CFU-EC formation was also associated
with the inflammatory response to endothelial injury
[26]. These CFU-ECs exhibit characteristics of mono-
cytes/macrophages and contribute to a paracrine
support of endothelial lining repair [26].
By contrast, “true EPCs” have been identified within
the CD45− non-haematopoietic fraction of the CD34+
circulating PCs and are capable of forming highly prolif-
erative late-outgrowth endothelial colonies. These cells,
also named endothelial colony-forming cells (ECFCs), be-
have as angioblasts with a specific ability to achieve
endothelial differentiation and contribute to de novo
vessel formation [24]. They are unlikely derived from
bone marrow, but rather belong to a pool of vascular
wall-resident precursors [11]. Owing to the extreme
scarcity of EPCs in peripheral blood, very few clinical
studies have tackled this cell population. These investi-
gations were restricted mainly to the cardiovascular field
and suggested the potential relevance of CD34+CD45−
EPC quantification as a reflection of inflammatory [27]
or mechanical vascular injury [28]. To our knowledge,
this CD34+CD45− EPC subset has never been investi-
gated in patients with SSc.
In addition, several soluble inflammatory endothelial
mediators, such as endothelin-1 [29] and soluble frac-
talkine (s-Fractalkine) [30], have been associated with
SSc pathogenesis. Elevated endothelin-1 levels were
shown to induce endothelial cell activation, fibroblast
differentiation and vascular remodelling [29]. This dis-
covery allowed for the therapeutic targeting of the
endothelin-1 pathway, which led to a real clinical benefit
in patients with pulmonary arterial hypertension [31]
and digital ulcers [32]. Fractalkine (chemokine [C-X3-C
motif] ligand 1 [CX3CL1]) is an endothelial membrane-
bound adhesion molecule and a soluble chemokine after
metalloprotease cleavage [33]. Increased endothelial cell
surface expression and circulating s-Fractalkine levels
have been described in inflammatory contexts of vascu-
lar injury, such as atherosclerosis [34] and immune
diseases, including SSc [30]. The upregulation of frac-
talkine on activated endothelial cells allows for the
recruitment and activation of immune cells expressing
chemokine (C-X3-C motif) receptor 1 (CX3CR1) [35].
Polymorphisms of CX3CR1 have been associated with SSc-
associated pulmonary arterial hypertension [36]. Accord-
ingly, the disruption of the interaction between fractalkine
and CX3CR1 has been shown to dampen the fibrotic
process in a murine model of cytokine-induced SSc [37].
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view of the endothelial status based on the combined as-
sessment of circulating biomarkers of endothelial inflam-
mation, injury and repair. Our objective was to delineate
specific profiles associated with SSc disease and severity.
Methods
Patients
Forty-five consecutive, unselected patients with SSc were
recruited at the Department of Internal Medicine,
Assistance Publique-Hôpitaux de Marseille (APHM). All
the enrolled patients had a score ≥9 for SSc according to
the 2013 American College of Rheumatology/European
League Against Rheumatism criteria [38]. Among the
patients were 44 women and 1 man with a median age
of 60.38 years (IQR 51.45–72.38 years) (Table 1).
Healthy volunteers (n = 41) were recruited for the study
by the Centre d’Investigation Clinique Marseille, APHM,
and used as control subjects. The control group
consisted of 38 women and 3 men with a median age of
55.97 years (IQR 53.56–59.64 years) (Table 1). Written
informed consent was obtained according to the Declar-
ation of Helsinki, and the study was approved by the
local ethics committee review board of Marseilles.
Clinical and standard biological assessment
All subjects had a physical examination and underwent
laboratory tests. Characteristics of the study population
are summarised in Table 1. Arterial stiffness was
assessed by measuring the right carotid-radial pulse
wave velocity (PWV) using a validated, non-invasive, au-
tomated method. The FMD of the brachial artery was
measured as previously reported [2].
Patients with SSc were classified as having limited cuta-
neous SSc or diffuse cutaneous SSc according to the criteria
established by van den Hoogen et al. [38]. The diseaseTable 1 Demographic characteristics and cardiovascular risk factors
Patients with SSc (n =
Sex, male/female, n 1/44
Age, years, median [IQR] 61.49 (±11.95) 60.4 [5
BMI, kg/m2, median [IQR] 23.05 (±4.63) 22.5 [20
Systolic blood pressure, mmHg 119.11 (±16.95) 120 [1
Diastolic blood pressure, mmHg 71.86 (±8.91) 72.5 [67
Resting heart rate, beats/minute 71.25 (±10.24) 70.5 [6
LDL cholesterol, g/L 3.29 (±1.32) 3.2 [2.36–
HDL cholesterol, g/L 1.72 (±0.43) 1.71 [1.4–
Triglycerides, g/L 1.14 (±0.47) 0.93 [0.81
Carotid-radial pulse wave velocity, m/second 11.05 (±3.32) 10.5 [8.1
Flow-mediated dilation, % 9.87 (±6.97) 9.3 [5.8–1
Abbreviations: BMI Body mass index, HDL High-density lipoprotein, LDL Low-density
Variables are described using mean (±SD) and median [IQR]duration, the presence of Raynaud’s phenomenon, pitting
scars, digital ulcers, digital gangrene or telangiectasia were
recorded. The modified Rodnan skin score (mRSS) was
graded on a scale of 0–3 with a maximum total score of 51.
Disease severity was measured on a scale of 0–4 according
to the Medsger severity scale [39]. Two groups of patients
were segregated on the basis of severity state: Group 1
comprised grades 0, 1 and 2, and group 2 consisted of
grades 3 and 4 (Table 2).
Concomitant treatments of patients with SSc are
described in Additional file 1: Table S1. Biological data
comprised white blood cell count, haemoglobin rate,
platelets count, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, triglycerides,
creatinine level and C-reactive protein (CRP) level
(Additional file 1: Table S2).Pulmonary involvement was
determined by pulmonary function tests, including
forced vital capacity (FVC), diffusing capacity of the lung
for carbon monoxide (DLCO) and DLCO divided by al-
veolar volume (DLCO/VA). Fibrosis was diagnosed on
the basis of chest computed tomography, with qualita-
tive criteria consisting of the presence of honeycombing,
ground-glass opacities, reticular abnormalities, traction
bronchiectasis and septal thickening. Systolic pulmonary
arterial pressure was measured by transthoracic echocar-
diography, and pulmonary hypertension was confirmed
by right heart catheterisation. Anti-nuclear antibodies
were assessed by indirect immunofluorescence analysis
of HEp-2 cells. Anti-centromere and anti-topoisomerase
I antibodies were measured by enzyme-linked immuno-
sorbent assay (ELISA).
Flow cytometric enumeration of endothelial
microparticles
Control and patient samples for EMP analysis were col-
lected and processed according to the current Internationalof the subjects
45) Control subjects (n = 41) P value
3/38 0.3437
1.5–72.4] 56.09 (±7.82) 56 [53.6–59.6] 0.0375
.2–23.8] 25.3 (±3.75) 24.9 [22.8–28.3] 0.0022
05–130.25] 127.7 (±14.1) 126 [119.25–135.25] 0.0141
.75–78.25] 79.15 (±9.71) 79 [73–84.25] 0.0006
4–76.25] 68.95 (±9.93) 70 [62.75–74] 0.3001
4.28] 3.69 (±0.79) 3.59 [3.17–4.13] 0.0978
1.95] 1.59 (±0.43) 1.51 [1.34–1.85] 0.1848
–1.48] 1.4 (±0.74) 1.25 [0.88–1.66] 0.1303
6–13] 10.11 (±3.01) 9.46 [7.62–12.05] 0.1855
4.76] 15.29 (±8.75) 12.35 [9.09–21.38] 0.0084
lipoprotein, SSc Systemic sclerosis
Table 2 Clinical characteristics of patients with systemic
sclerosis
Patients with SSc (n = 45)
Diffuse/limited cutaneous subtype 16 (35.6%)/29 (64.4%)
Anti-centromere/anti-topoisomerase I 21 (46.7%)/19 (42.2%)
Disease duration ≤3 years/˃3 years 15 (34.1%)/29 (65.9%)
Medsger severity scale
Grades 0, 1 and 2 1 (2.2%), 14 (31.1%) and 7 (15.6%)
Grades 3 and 4 22 (48.9%) and 1 (2.2%)
Pitting scars 24 (53.3%)
Digital ulcers 18 (40.0%)
Digital gangrene 4 (8.9%)
Telangiectasia 29 (64.4%)
Pulmonary function tests
DLCO, % 97.3 [88.8–103.5]
DLCO/VA, % 67.4 [61.35–78.2]
FVC, % 99.3 [84.1–115.6]
Pulmonary fibrosis 7 (18.9%)
Systolic pulmonary arterial pressurea 33 [27.8–37.5]
DLCO Diffusing capacity of the lung for carbon monoxide, FVC Forced vital
capacity, VA alveolar volume
Qualitative variables are described using counts and percentages. Quantitative
variables are described using median [first quartile–third quartile]
aTransthoracic echocardiography assessment
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Briefly, blood samples collected into 5-ml BD Vacutainer
tubes containing 0.129 mol/L sodium citrate (BD Diagnos-
tics, Franklin Lakes, NJ, USA) were subjected to two suc-
cessive centrifugations (2500 × g for 15 minutes at room
temperature), and platelet-free plasma (PFP) was prepared.
The PFP was homogenised before being aliquoted and
stored at −80 °C until use. Annexin V-fluorescein isothio-
cyanate (FITC) and the following fluorescent antibody
reagents were procured from Beckman Coulter (Villepinte,
France): CD31-phycoerythrin (PE) (clone 1 F11) and
CD41-PE-cyanine 7 (CD41-PC7) (clone P2), as well as their
respective isotype controls.
EMPs were enumerated by high-sensitivity flow cytome-
try following standardisation as previously described [41].
In brief, 30 μl of PFP was incubated with the appropriate
amount of specific antibody or isotype control matched in
terms of final concentration and fluorescence back-
grounds, plus 10 μl of annexin V-FITC. Each stained
sample was analysed on a NAVIOS-3 laser instrument
(Beckman Coulter Life Sciences, Miami, FL, USA) follow-
ing a protocol standardised with Megamix-Plus FSC beads
(BioCytex, Marseille, France) with sizes ranging from 0.3
to 0.9 μm. EMPs were defined as annexin V+/CD31+CD41
− events. The absolute EMP counts (events per microlitre)
were determined using ad hoc counting beads
(CytoCount™; Dako, Glostrup, Denmark).Enumeration of circulating endothelial cells
CECs were isolated by immunomagnetic separation
using Dynabeads coated with anti-CD146 monoclonal
antibody (Life Technologies, Carlsbad, CA, USA) from
1 ml of blood samples collected into 5-ml ethylenedi-
aminetetraacetic acid (EDTA) Vacutainer tubes. CECs
were identified on the basis of previously described
consensual morphologic and immunologic criteria [42]:
rosette cell staining with acridine orange, size >15 μm,
bearing more than five beads, and Ulex europeaus
lectin-1 binding. Counting was performed with a fluor-
escence microscope.
Assessment of colony-forming unit-endothelial cells
CFU-ECs were produced according to the protocol ini-
tially described by Hill et al. [25] and adapted by Smadja
et al. [43]. Mononuclear cells (MNCs) were obtained by
density gradient isolation and cultured with the EndoCult®
Liquid Medium Kit (STEMCELL Technologies, Vancou-
ver, BC, Canada) according to the manufacturer’s instruc-
tions. In short, MNCs were re-suspended in complete
EndoCult® medium and seeded at 5 × 106 cells/well in
fibronectin-coated tissue culture plates (BD Biosciences,
San Jose, CA, USA). After 48 h, to obtain CFU-ECs, non-
adherent cells were collected and plated in EndoCult® buf-
fer at 106 cells/well in 24-well fibronectin-coated plates.
CFU-EC colonies were counted after another 3 days, as
recommended by the manufacturer.
Enumeration and characterisation of circulating
progenitor cells by flow cytometry
Blood samples were collected into 5-ml, EDTA-coated
BD Vacutainer tubes. CD34+CD45+ haematopoietic pro-
genitor cells (CD34+CD45+ HPCs) and CD34+CD45−
EPCs were enumerated with a whole-blood flow cytome-
try protocol adapted from the standardised International
Society of Hematotherapy and Graft Engineering single-
platform sequential gating strategy [44]. Briefly, 100 μl
of blood was stained with FITC-CD45 antibody, PE-
CD34 antibody or PE-immunoglobulin G1 (IgG1), and
7-aminoactinomycin D (7-AAD) (Stem-Kit Reagents;
Beckman Coulter Life Sciences), according to the manu-
facturer’s instructions. After lysis of erythrocytes, flow
count beads were added to each sample for absolute
value determination, and samples were analysed with a
NAVIOS flow cytometer equipped with CXP software
(Beckman Coulter Life Sciences). At least 75,000 CD45+
cells were acquired per run. CD34+CD45+ HPCs and
CD34+CD45− EPCs were identified within 7-AAD-
negative viable cells displaying forward scatter (FSC)/
side scatter (SSC) characteristics corresponding to the
lymphocyte cluster and CD45dim or CD45− expression.
The results were expressed as absolute numbers of
CD34+CD45+ HPCs and CD34+CD45− EPCs per
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Additional file 2: Figure S1.
Because CD34+CD45+CD133+ PCs and CD34+CD45
+KDR+ PCs, identified as CACs, are present in low levels
in peripheral blood, these progenitor subsets were quanti-
fied using a four-color flow cytometry strategy after direct
immunolabelling of isolated peripheral blood mono-
nuclear cells (PBMCs). PBMCs were isolated from 7 ml of
heparinised peripheral blood by density gradient centrifu-
gation with lymphocyte separation medium (PAA Labora-
tories, Pasching, Austria), and they were labelled with
10 μl of 7-AAD viability dye, 10 μl of FITC-CD34 anti-
body (Beckman Coulter), 10 μl of ECD-CD45 antibody
(Beckman Coulter) and 10 μl of PE-CD133 antibody (Mil-
tenyi Biotec, Bergisch Gladbach, Germany) or PE-KDR
antibody (R&D Systems, Abingdon, UK). A 10-μl quantity
of concentration-matched, PE-conjugated murine IgG1
antibody was used as a fluorescence minus one control.
After incubation for 20 minutes at room temperature,
cells were washed and re-suspended in 500 μl of PBS, and
then analysed using a NAVIOS flow cytometer.
After selection of 7-AAD-negative cells, CD133+ and
KDR+ cells were identified within CD34+CD45+ cells
displaying FSC/SSC characteristics corresponding to the
lymphocyte cluster. At least 5 × 105 viable cells were ac-
quired per run. The percentage of CD133+ or KDR+ cells
among CD34+CD45+ cells was determined. Results were
expressed as absolute values per millilitre of blood of
CD34+CD45+CD133+ PCs, and CD34+CD45+KDR+ PC
values were obtained by multiplying the percentage of
each cellular subpopulation by the absolute values of
CD34+CD45+ HPCs determined as described above. The
literature-based identification criteria and characteristics
of the endothelial cell populations of the endothelial cell
population investigated in the present study are
summarised in the Additional file 1: Table S3.
Analysis of circulating vascular endothelial growth factor,
endothelin-1 and soluble fractalkine levels
Circulating levels of vascular endothelial growth factor
(VEGF), endothelin-1 and s-Fractalkine (CX3CL1) were
measured in serum using commercially available ELISA
kits obtained from R&D Systems Inc. (Minneapolis, MN,
USA). Assays were performed according to the manufac-
turer’s instructions.
Statistical analysis
Quantitative variables were described using mean (±SD)
or median and IQR [first quartile–third quartile] accord-
ing to their distribution. The normality of the distribution
was assessed graphically. Qualitative variables were de-
scribed using counts and percentages. The correlations
between quantitative variables were performed using
Spearman’s correlation. Student’s t test and the Mann-Whitney U test were performed to compare using quanti-
tative variables of the two groups. The chi-square test or
Fisher’s exact test was used to compare qualitative vari-
ables. P values <0.05 were considered significant.
A multivariate model based on logistic regression with
a robust estimator (generalised estimating equation with
M-estimator) was used to assess independent factors
associated with SSc. A stepwise backward elimination
procedure was performed to conserve variables with an
adjusted P value <0.05. Variables first introduced into
the univariate model were those with a P value <0.20.
To analyse the association of the variables with clinical
characteristics (cutaneous subtype, disease duration groups
of severity of patients with SSc defined by Medsger severity
scale), we first used quantitative values of these biomarkers.
We next aimed to deepen the analysis in an exploratory
prospect evaluation by segregating groups. We used deci-
sion trees with the chi-square automatic interaction detec-
tion (CHAID) method to assess whether cut-off values of
these biomarker levels could enable us to discriminate these
two groups of severity states in a dichotomous manner.
Analyses were performed using Prism 5.0 (GraphPad Soft-
ware, La Jolla, CA, USA) and IBM SPSS Statistics version
20.0 (IBM, Armonk, NY, USA) software.
Results
Characteristics of the study population
The characteristics of the study population, including car-
diovascular risk factors and vascular phenotypes, are sum-
marised in Table 1. SSc-related features are shown in
Table 2, and the ongoing treatments are reported in Add-
itional file 1: Table S1. The patient sample comprised 44
women and 1 man with a median age of 60.38 years [IQR
51.45–72.38 years] and median disease duration of
15 years. The control group of healthy volunteers con-
sisted of 38 women and 3 men with a median age of
55.97 years [IQR 53.56–59.64 years]. Sixteen patients
(35.6%) had diffuse cutaneous SSc, and 29 patients
(64.4%) had limited cutaneous SSc. The demographic
characteristics of patients with SSc were comparable to
those of the healthy control subjects, except for higher
mean age, lower body mass index (BMI) and lower arterial
blood pressure observed in the patients with SSc (Table 1).
The prevalence of cardiovascular risk factors, including dia-
betes, tobacco consumption, familial history of coronary
disease, hypercholesterolemia, arterial hypertension, seden-
tary lifestyle, menarche, hormone treatment and atheroma
deposits on carotid artery assessed by Doppler ultrasonog-
raphy did not significantly differ between the two groups
(data not shown). The right carotid-radial PWV did not sig-
nificantly differ between the two groups, accounting for a
similar arterial stiffness. However, patients with SSc had a
significantly lower endothelium-dependent FMD of the
brachial artery (Table 1).
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with SSc and control subjects regarding biological pa-
rameters such as white blood cell count, haemoglobin
level and creatinine clearance. All of the values remained
within the normal range. CRP level was slightly higher
in the patient group than in healthy control subjects
(Additional file 1: Table S2).Circulating cellular biomarkers of endothelial activation
and injury in patients with SSc
Because EMPs and CECs reflect endothelial cell activa-
tion and injury, we aimed to investigate these markers in
patients with SSc using standardised methods. The
patients with SSc had significantly higher plasma levels
of EMPs (93.5/μl, IQR 64.75–130.5) than control
subjects (33/μl, IQR 21–46.5; P < 0.0001) (Fig. 1). Com-
parable levels of CECs were found in patients with SSc
(2/ml of blood, IQR 1–8.5) and healthy control subjects
(2.5/ml of blood, IQR 0–16.5).Fig. 1 Quantification of endothelial microparticles (EMPs) in the
peripheral blood of healthy control subjects (HCs) and patients with
systemic sclerosis (SSc). EMP numbers (nb) were defined as annexin
V+/CD31+CD41− events and quantified by high-sensitivity flow
cytometry using counting beads. *** P < 0.0005Colony forming unit-endothelial cell generation in pa-
tients with SSc
The assessment of CFU-ECs established by culture of
MNCs from patients with SSc and healthy control sub-
jects revealed higher numbers of colonies in patients
with SSc (11 per 106 MNCs, IQR 3–20.25) than in
healthy control subjects (3 per 106 MNCs, IQR 0.85–8;
P = 0.0032) (Additional file 2: Figure S2).
Flow cytometric analysis of circulating CD34+ progenitor
cell subsets in patients with SSc
To cover most of the literature-reported phenotypes of
EPCs and CACs, we enumerated various circulating
CD34+ cell populations, including total CD34+ PCs,
CD34+CD45− EPCs and HPCs, CD34+CD45+ HPCs,
immature CD34+CD45+CD133+ PCs and CD34+CD45
+KDR+ PCs. We observed that patients with SSc had
significantly higher numbers of total circulating CD34+
PCs (2074.5/ml, IQR 1459.5–2578) than control subjects
(1555/ml, IQR 1225–1960; P = 0.0442). The number of
circulating HPCs did not differ significantly between
patients with SSc and control subjects (1662/ml, IQR
1297.7–2134.2, versus 1485/ml, IQR 1117.5–1912.5; P
= 0.4247) (Fig. 2a). Moreover, KDR+ PCs (37/ml, IQR
5.5–100.5, versus 57.01/ml, IQR 27.5–96; P = 0.243)
and CD133+ PCs (1185/ml, IQR 827–1456, versusFig. 2 Circulating CD34+ progenitor cells (PCs) subsets counts in
healthy control subjects (HC) and patients with systemic sclerosis
(SSc). Number (nb) of (a) CD34+CD45+ haematopoietic progenitor
cells (HPCs), (b) CD34+KDR+ PCs, (c) CD34+CD133+ PCs and (d)
non-haematopoietic CD34+CD45− endothelial PCs were determined
by flow cytometric analysis. *** P < 0.0005. n.s Non-significant
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fer between the two groups (Fig. 2b and c). The number
of circulating CD34+CD45− EPCs was significantly
higher in patients with SSc (247/ml, IQR 74.2–508.2,
versus 40/ml, IQR 0–82.5; P <0.0001) (Fig. 2d). No cor-
relation was found between EMPs (marker of endothe-
lial activation) and PC subsets (CFU-ECs, CD34+ PCs
and CD34+CD45− EPCs) in patients with SSc.
Elevation of soluble endothelial biomarkers in patients
with SSc
First, we investigated the circulating levels of the endo-
thelial biomarkers VEGF, s-Fractalkine and endothelin-1
in patients with SSc and healthy control subjects.
Median serum concentrations of these biomarkers were
significantly elevated in patients with SSc compared with
control subjects: VEGF (57 pg/ml, IQR 39–118, versus
42 pg/ml, IQR 26–78.7; P = 0.0357) (Fig. 3a), endothelin-
1 (1.68 pg/ml, IQR 1.3–2.0, versus 1.2 pg/ml, IQR 1.0–
1.3; P < 0.0001) (Fig. 3b) and s-Fractalkine (465.45 pg/
ml, IQR 366.4–598.5, versus 186 pg/ml, IQR 140.5–
268.0 pg/ml; P < 0.0001) (Fig. 3c). Next, we assessed
whether these soluble biomarkers correlated with theFig. 3 Soluble endothelial biomarker concentrations in patients with
systemic sclerosis (SSc) compared with healthy control subjects (HC). a
Vascular endothelial growth factor (VEGF). b Endothelin-1. c Soluble
fractalkine (s-Fractalkine). d Correlation between s-Fractalkine and
CD34+CD45− endothelial progenitor cell (EPC) counts (nb). Correlation
was established using the non-parametric Spearman’s correlation
coefficient (rs). * P < 0.05; *** P < 0.0005. n.s= non-significantaforementioned cellular biomarkers in patients with SSc.
We observed a significant positive correlation between
s-Fractalkine levels and CD34+CD45− EPC numbers (rs =
0.35, P = 0.0166) (Fig. 3d). No other correlation was noted
in patients with SSc.
Association of endothelial biomarkers with SSc
The univariate analyses showed that the variables age,
BMI, creatinine clearance and CRP, as well as the endo-
thelial biomarkers EMPs, CFU-ECs, CD34+ PCs, CD34
+CD45− EPCs, VEGF, endothelin-1 and s-Fractalkine,
were different between healthy control subjects and
patients with SSc (P < 0.05) (Table 3).
In the multivariate model including all of these vari-
ables, EMPs, endothelin-1 and s-Fractalkine were inde-
pendent markers associated with SSc (Table 4).
Because s-Fractalkine level and CD34+CD45− EPC
count were correlated, a multivariate model with the
same variables except for s-Fractalkine was tested. In
this model, EMPs (P = 0.007), endothelin-1 (P = 0.001)
and CD34+CD45− EPCs (P = 0.025) were independently
associated with SSc (Additional file 1: Table S4).
Association of endothelial biomarkers with disease
clinical characteristics and severity
We investigated whether each of the independent bio-
markers associated with SSc (i.e., EMPs, CD34+CD45−
EPCs, endothelin-1 and s-Fractalkine) could be associ-
ated with the clinical characteristics of patients with SSc.
The first level of analysis of the quantitative values of
these biomarkers did not allow for identifying markers
that discriminated the cutaneous subtype, disease dur-
ation, clinical characteristic and group of severity
defined by the Medsger severity scale (P > 0.05 for all).
The CHAID algorithm allowed us to propose cut-off
values for s-Fractalkine (486 pg/ml), CD34+CD45− EPC
level (395/ml) and endothelin-1 (1.26 ng/ml). According
to this approach, values of EMPs could not be discrimi-
nated in a dichotomous manner.
The frequency of patients with more severe disease
was higher in the group with s-Fractalkine concentra-
tions above the cut-off value (P = 0.041). Patients belong-
ing to this group also had decreased DLCO/VA and a
higher frequency of pulmonary fibrosis (Table 5).
Patients with lower FVC had CD34+CD45− EPC num-
bers above the cut-off value (P = 0.0282). No significant
difference was noted between patients with endothelin-1
levels less than or greater than the cut-off value.
Discussion
The non-invasive monitoring of endothelial alterations is
a challenge for physicians to better assess the severity of
the disease and to sustain the development of therapeutic
approaches [45, 46]. Based on an integrative analysis of
Table 3 Circulating endothelial biomarkers studied in univariate analysis
Patients with SSc Control subjects P value
Endothelial cellular markers
EMPs, n/μl 93.5 [64.75–130.5] 33 [21– 46.5] <0.0001***
CECs, n/ml 2 [1–8.5] 2.5 [0–16,5] 0.7677
PC subsets
CFU-ECs, n/106 MNCs 11 [3–20.25] 3 [0.85–8] 0.0032**
CD34+ PCs, n/ml 2074.5 [1459.5–2578] 1555 [1225–1960] 0.0442*
CD34+CD45+ PCs, n/ml 1662 [1297.7–2134.2] 1485 [1117.5–1912.5] 0.4247
KDR+ PCs, n/ml 37 [5.5–100.5] 57.01 [27.5–96] 0.243
CD133+ PCs, n/ml 1185 [827–1456] 1287 [929.71–1705.13] 0.2463
CD34+CD45− EPCs, n/ml 247 [74.2–508.2] 40 [0–82.5] <0.0001***
Soluble endothelial markers
VEGF, pg/ml 57 [39–118] 42 [26–78.7] 0.0357*
Endothelin-1, pg/ml 1.68 [1.3–2.0] 1.2 [1.0–1.3] <0.0001***
s-Fractalkine, pg/ml 465.45 [366.4–598.5] 186 [140.5–268.0] <0.0001***
Abbreviations: EMP Endothelial microparticle, CEC Circulating endothelial cell, CFU-EC Colony-forming unit-endothelial cell, EPC Endothelial progenitor cell, KDR
Kinas insert domain receptor, PC Progenitor cell, VEGF Vascular endothelial growth factor, s-Fractalkine Soluble fractalkine, MNC Mononuclear cell, SSc
Systemic sclerosis * P < 0.05; 0.001 < **P < 0.01; *** P < 0.0005
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identifies the mobilisation of CD34+CD45− EPCs and high
levels of s-Fractalkine as specific features of SSc-
associated vascular activation and disease severity.
We confirmed the impaired endothelial function
assessed by FMD in patients with SSc [2]. Consistent
with a disrupted endothelial homeostasis [9], we con-
firmed that EMP release is increased in patients with
SSc. The EMPs can promote or aggravate pre-existing
vascular dysfunction in cardiovascular diseases [4] and
have been shown to be deleterious via the induction of
an oxidative burst in a murine model of SSc [47]. In the
present study, EMP levels were not associated with dis-
ease severity. Researchers in other studies reported de-
creased levels of EMPs in SSc [48] or their association
with lung and skin involvement, but they did not con-
sider annexin V binding as a criterion to define EMPs
[49]. Our observations indicate that the release ofTable 4 Multivariate logistic regression analysis for systemic
sclerosis with robust estimator
Variables OR (95% CI) P value
EMPs 1.002 (1.000-1.004) 0.015
Endothelin-1 1.044 (1.009-1.082) 0.012
s-Fractalkine 92.388 (2.729-3127.533) 0.035
EMP Endothelial microparticle, s-Fractalkine Soluble fractalkine
Variables introduced into this multivariate model were selected after
univariate analysis (P < 0.2). The final model was established after stepwise
backward elimination of non-significant variables (i.e., age, body mass index,
creatinine, C-reactive protein, colony-forming unit-endothelial cells, CD34+
progenitor cells, CD34+CD45− endothelial progenitor cells and vascular
endothelial growth factor). Independent variables associated with systemic
sclerosis with an adjusted P < 0.05 were conservedannexin V+ EMPs primarily reflects the activated endo-
thelial status. Such activation might not result in a
significant insult of the endothelial monolayer, given that
the release of EMPs was not associated with CEC eleva-
tion assessed by anti-CD146-based immunomagnetic
separation. Indeed, this standardised assay has been
shown to quantify mature endothelial cells that are de-
tached from the endothelial monolayer as a consequence
of pathological processes that disrupt its integrity [6].
Such a restricted definition criterion of CECs might ex-
plain discrepancies observed in other studies in which
researchers used flow cytometric approaches to quantify
CECs in patients with SSc [14].
We also present the first evidence that enhanced levels
of circulating CD34+CD45− EPCs occur in patients with
SSc, whereas these cells were barely detectable in
healthy control subjects. The association between CD34
+CD45− EPC levels and decreased FVC may suggest that
these cells are mobilised as a response to lung
involvement-induced hypoxia. In accordance with this
hypothesis, patients with SSc exhibited high levels of
VEGF, the main pro-angiogenic factor promoting the
mobilisation of PCs from the bone marrow [11].
Interestingly, CD34+CD45− EPC counts were increased,
whereas all the haematopoietic lineage-related CD34+
PC subsets defined by CD45dim expression and CD133
or KDR markers remained unchanged in the analysed
cohort. These data may indicate defective mobilisation of
the bone marrow-derived pool of these CACs, as reported
by Kuwana et al. [13]. In line with this hypothesis, quanti-
tative and qualitative alterations of this bone marrow pool
of HPCs have been described in SSc [17]. Of note, our
Table 5 Clinical and laboratory data of patients with systemic sclerosis, depending on soluble fractalkine concentrations
s-Fractalkine >486 pg/ml (n = 16) s-Fractalkine <486 pg/ml (n = 25) P value
Clinical features
Age, years, median [IQR] 55.06 [50.94–72.84] 62.52 [52.8–71.33] 0.56
Duration, years, median [IQR] 5.5 [3–12.75] 8 [3–12.5] 0.8933
Pitting scars or skin ulcers, n 11/16 14/25 0.41
Pulmonary fibrosis, n 3/16 3/22 <0.0001***
FVC, %, median [IQR] 98.5[85.75–113.3] 95.9 [82–111.3] 0.558
DLCO/VA, %, median [IQR] 62 [53–76] 75 [63.5–81.45] 0.0445*
Oesophagus, n 13/16 13/25 0.0579
Telangiectasia, n 9/16 20/25 0.1030
mRSS, median [IQR] 11.5 [5.25–23] 10 [5–16] 0.6166
Pulmonary arterial pressure, mmHg, median [IQR] 27 [21.25–34] 25 [20–31] 0.32
Severity grades 0, 1 and 2, n 4/16 15/25 0.0284*
Severity grades 3 and 4, n 12/16 10/25 0.0284*
Laboratory findings
Anti-topoisomerase I antibody, n 6/16 13/25 0.3638
Anti-centromere antibody, n 7/16 12/25 0.79
Abbreviations: DLCO Diffusing capacity of the lung for carbon monoxide, CEC Circulating endothelial cell, FVC Forced vital capacity, mRSS Modified Rodnan skin
score, VA Alveolar volume, s-Fractalkine Soluble fractalkine
Qualitative variables are described using frequencies. Quantitative variables are described using median and IQR [first quartile–third quartile] * P < 0.05; *** P < 0.0005
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cells co-expressing CD133, CD34 and KDR. Although this
phenotype was initially proposed to identify the immature
part of EPC populations, we failed to detect these cells in
both healthy control subjects and patients with SSc (data
not shown), as recently published [50].
The functional ability of the cells derived from mobi-
lised CD34+CD45− EPCs could not be analysed in the
present study, because the clonogenic and angiogenic
assays require large blood samples that are hardly ob-
tainable from patients with SSc. Nevertheless, Avouac
et al. observed that the number of late-outgrowth ECFCs
derived in culture was not increased in patients with SSc
in comparison with control subjects [16]. Along with
our results, we can assume that the mobilisation of
CD34+CD45− EPCs may represent a quantitative
response to activation that is not translated in the acqui-
sition of progenitor-associated vascular regenerative
potential.
In this study, the mobilisation of CD34+CD45− EPCs
occurred in a context of vascular inflammation, as re-
vealed by the moderate elevation of CRP and CFU-ECs
and the increase in endothelial activation biomarkers
such as EMPs, endothelin-1 and s-Fractalkine. Further-
more, we established a positive correlation between the
CD34+CD45− EPC levels and the circulating levels of s-
Fractalkine in patients with SSc. Animal models suggest
that the fractalkine/CX3CR1 pathway is involved in the
recruitment of EPCs to the ischaemic sites during stroke
[51] and regulates progenitor-dependent endothelialrepair during atherosclerosis [52]. Moreover, we have
previously shown that membrane-bound fractalkine can
play a role in controlling EPC homeostasis in the allor-
eactive environment of renal transplant [53]. The first
evidence provided here of the interplay between s-
Fractalkine and EPCs in the context of SSc may deserve
further mechanistic investigation. In the present study,
the SSc group exhibited reduced FMD values but similar
arterial stiffness in comparison with the control group,
suggesting that the alterations of the biological markers
observed here were due to the SSc-related endothelial
dysfunction rather than to atherosclerosis.
The limits of our exploratory study are inherent to a
one-point biological assessment performed in a low
number of patients with heterogeneous clinical pheno-
types. Furthermore, the impact of long-standing therap-
ies could not be appreciated. This could also account in
part for the lack of association between endothelin-1
levels and disease severity, notably in patients treated
with endothelin-1 receptor antagonists. s-Fractalkine
was the only soluble marker found to be associated with
disease severity in SSc in this study [30]. Such an obser-
vation is consistent with the involvement of the fractalk-
ine/CX3CR1 pathway in the mechanisms linking the
endothelial inflammation to the onset of fibrosis.
Conclusions
Our data identify a specific signature of inflammatory
endothelial activation that encompasses high levels of
EMPs, CFU-ECs, endothelin-1, VEGF and s-Fractalkine
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tion of CD34+CD45− EPCs. s-Fractalkine and CD34
+CD45− EPCs seem to be associated with lung involve-
ment. Further studies are needed to determine the exact
prognostic value of the combined assessment of s-
Fractalkine and CD34+CD45− EPCs in patients with SSc.
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